TRAIL overexpression co-regulated by Egr1 and HRE enhances radiosensitivity of hypoxic A549 cells depending on its apoptosis inducing role

Yang,Yan-Ming; Fang,Fang; Li,Xin; Yu,Lei; Wang,Zhi-Cheng

doi:10.3892/or.2016.5271

TRAIL overexpression co-regulated by Egr1 and HRE enhances radiosensitivity of hypoxic A549 cells depending on its apoptosis inducing role

Authors:
- Yan-Ming Yang
- Fang Fang
- Xin Li
- Lei Yu
- Zhi-Cheng Wang
View Affiliations

Affiliations: Department of Radiotherapy, Second Hospital of Jilin University, Changchun, Jilin 130041, P.R. China, Key Laboratory of Radiobiology, Ministry of Health, School of Public Health, Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: November 23, 2016 https://doi.org/10.3892/or.2016.5271
Pages: 533-539

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ionizing radiation can upregulate the expression levels of TRAIL and enhance tumor cell apoptosis. While Early growth response 1 (Egr1) gene promoter has radiation inducible characteristics, the expression for exogenous gene controlled by Egr1 promoter could be enhanced by ionizing radiation, but its efficiency is limited by tissue hypoxia. Hypoxia response elements (HREs) are important hypoxic response regulatory sequences and sensitivity enhancers. Therefore, we chose TRAIL as the gene radiotherapy to observe whether it is regulated by Egr1 and HER and its effects on A549 cells and its mechanism. The pcDNA3.1-Egr1-TRAIL (pc-E-hsT) and pcDNA3.1-HRE/Egr1-TRAIL (pc-H/E-hsT) plasmids containing Egr1-hsTRAIL and HRE/Egr1-hsTRAIL were transfected into A549 cells, the cells were treated by hypoxia and radiation. The TRAIL mRNA in the cells and protein concentration in the culture supernatants were measured by RT-PCR and ELISA, respectively. Mean lethal dose D0 value was evaluated with colony forming assay. The cell apoptotic rates were analyzed by FCM and TUNEL assay. Expression of DR4, DR5 and cleaved caspase-3 proteins were analyzed by western blotting. It showed that TRAIL mRNA expression and TRAIL concentration all significantly increased under hypoxia and/or radiation. D0 value of pc-H/E‑hsT transfected cells under hypoxia was lowest, indicating more high radiosensitivity. Hypoxia could not cause the pc-E-hsT transfected cell apoptotic rate increase, but there were promoting effects in pc-H/E-hsT transfected cells. DR4 had not obvious change in pc-E-hsT and pc-H/E-hsT transfected cells under normoxic and hypoxic condition, otherwise, DR5 and cleaved caspase-3 increased mostly in pc-H/E-hsT transfected cells under hypoxic condition. TRAIL overexpression was co-regulated by Egr1 and HRE. TRAIL might promote hypoxic A549 cell radiosensitivity and induce apoptosis depending on DR5 to caspase-3 pathways.

View Figures

View References

1	Grade M, Wolff HA, Gaedcke J and Ghadimi BM: The molecular basis of chemoradiosensitivity in rectal cancer: Implications for personalized therapies. Langenbecks Arch Surg. 397:543–555. 2012. View Article : Google Scholar : PubMed/NCBI
2	Vogelstein B and Kinzler KW: Cancer genes and the pathways they control. Nat Med. 10:789–799. 2004. View Article : Google Scholar : PubMed/NCBI
3	Woynarowska BA, Roberts K, Woynarowski JM, MacDonald JR and Herman TS: Targeting apoptosis by hydroxymethylacylfulvene in combination with gamma radiation in prostate tumor cells. Radiat Res. 154:429–438. 2000. View Article : Google Scholar : PubMed/NCBI
4	Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, et al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 3:673–682. 1995. View Article : Google Scholar : PubMed/NCBI
5	Perlstein B, Finniss SA, Miller C, Okhrimenko H, Kazimirsky G, Cazacu S, Lee HK, Lemke N, Brodie S, Umansky F, et al: TRAIL conjugated to nanoparticles exhibits increased anti-tumor activities in glioma cells and glioma stem cells in vitro and in vivo. Neuro Oncol. 15:29–40. 2013. View Article : Google Scholar : PubMed/NCBI
6	Tucker-Kellogg L, Shi Y, White JK and Pervaiz S: Reactive oxygen species (ROS) and sensitization to TRAIL-induced apoptosis, in Bayesian network modelling of HeLa cell response to LY303511. Biochem Pharmacol. 84:1307–1317. 2012. View Article : Google Scholar : PubMed/NCBI
7	Niemoeller OM and Belka C: Radiotherapy and TRAIL for cancer therapy. Cancer Lett. 332:184–193. 2013. View Article : Google Scholar : PubMed/NCBI
8	Li YB, Guo CX, Wang ZC, Dong LH, Guan F, Liu Y, Wang HF, Sun ZW and Gong SL: Radiosensitization of breast cancer cells by TRAIL-endostatin-targeting gene therapy. Neoplasma. 60:613–619. 2013. View Article : Google Scholar : PubMed/NCBI
9	Mahalingam D, Szegezdi E, Keane M, de Jong S and Samali A: TRAIL receptor signalling and modulation: Are we on the right TRAIL? Cancer Treat Rev. 35:280–288. 2009. View Article : Google Scholar : PubMed/NCBI
10	Sprick MR, Rieser E, Stahl H, Grosse-Wilde A, Weigand MA and Walczak H: Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO J. 21:4520–4530. 2002. View Article : Google Scholar : PubMed/NCBI
11	Datta R, Rubin E, Sukhatme V, Qureshi S, Hallahan D, Weichselbaum RR and Kufe DW: Ionizing radiation activates transcription of the EGR1 gene via CArG elements. Proc Natl Acad Sci USA. 89:10149–10153. 1992. View Article : Google Scholar : PubMed/NCBI
12	Weichselbaum RR, Hallahan DE, Sukhatme VP and Kufe DW: Gene therapy targeted by ionizing radiation. Int J Radiat Oncol Biol Phys. 24:565–567. 1992. View Article : Google Scholar : PubMed/NCBI
13	Liu LL, Smith MJ, Sun BS, Wang GJ, Redmond HP and Wang JH: Combined IFN-gamma-endostatin gene therapy and radiotherapy attenuates primary breast tumor growth and lung metastases via enhanced CTL and NK cell activation and attenuated tumor angiogenesis in a murine model. Ann Surg Oncol. 16:1403–1411. 2009. View Article : Google Scholar : PubMed/NCBI
14	Yang W and Li XY: Anti-tumor effect of pEgr-interferon-γ-endostatin gene-radiotherapy in mice bearing Lewis lung carcinoma and its mechanism. Chin Med J (Engl). 118:296–301. 2005.PubMed/NCBI
15	Li ZL, Liang S, Wang ZC, Li YB, Guo CX, Fang F, Gong SL and Lin CH: Expression of Smac induced by the Egr1 promoter enhances the radiosensitivity of breast cancer cells. Cancer Gene Ther. 21:142–149. 2014. View Article : Google Scholar : PubMed/NCBI
16	Weichselbaum RR, Kufe DW, Advani SJ and Roizman B: Molecular targeting of gene therapy and radiotherapy. Acta Oncol. 40:735–738. 2001. View Article : Google Scholar : PubMed/NCBI
17	Pines A, Bivi N, Romanello M, Damante G, Kelley MR, Adamson ED, D'Andrea P, Quadrifoglio F, Moro L and Tell G: Cross-regulation between Egr-1 and APE/Ref-1 during early response to oxidative stress in the human osteoblastic HOBIT cell line: Evidence for an autoregulatory loop. Free Radic Res. 39:269–281. 2005. View Article : Google Scholar : PubMed/NCBI
18	Wang WD, Chen ZT, Li R, Li DZ, Duan YZ and Cao ZH: Enhanced efficacy of radiation-induced gene therapy in mice bearing lung adenocarcinoma xenografts using hypoxia responsive elements. Cancer Sci. 96:918–924. 2005. View Article : Google Scholar : PubMed/NCBI
19	Greco O, Joiner MC, Doleh A, Powell AD, Hillman GG and Scott SD: Hypoxia- and radiation-activated Cre/loxP ‘molecular switch’ vectors for gene therapy of cancer. Gene Ther. 13:206–215. 2006. View Article : Google Scholar : PubMed/NCBI
20	Donadelli M, Pozza E Dalla, Scupoli MT, Costanzo C, Scarpa A and Palmieri M: Intracellular zinc increase inhibits p53(−/−) pancreatic adenocarcinoma cell growth by ROS/AIF-mediated apoptosis. Biochim Biophys Acta. 1793:273–280. 2009. View Article : Google Scholar : PubMed/NCBI
21	Pauwels B, Korst AE, de Pooter CM, Pattyn GG, Lambrechts HA, Baay MF, Lardon F and Vermorken JB: Comparison of the sulforhodamine B assay and the clonogenic assay for in vitro chemoradiation studies. Cancer Chemother Pharmacol. 51:221–226. 2003.PubMed/NCBI
22	Ding M, Li R, He R, Wang X, Yi Q and Wang W: p53 activated by AND gate genetic circuit under radiation and hypoxia for targeted cancer gene therapy. Cancer Sci. 106:1163–1173. 2015. View Article : Google Scholar : PubMed/NCBI
23	Cao XM, Koski RA, Gashler A, McKiernan M, Morris CF, Gaffney R, Hay RV and Sukhatme VP: Identification and characterization of the Egr-1 gene product, a DNA-binding zinc finger protein induced by differentiation and growth signals. Mol Cell Biol. 10:1931–1939. 1990. View Article : Google Scholar : PubMed/NCBI
24	Min FL, Zhang H and Li WJ: Current status of tumor radiogenic therapy. World J Gastroenterol. 11:3014–3019. 2005. View Article : Google Scholar : PubMed/NCBI
25	Bickenbach KA, Veerapong J, Shao MY, Mauceri HJ, Posner MC, Kron SJ and Weichselbaum RR: Resveratrol is an effective inducer of CArG-driven TNF-alpha gene therapy. Cancer Gene Ther. 15:133–139. 2008. View Article : Google Scholar : PubMed/NCBI
26	Brown JM and Wilson WR: Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 4:437–447. 2004. View Article : Google Scholar : PubMed/NCBI
27	Yang TJ and Ho AY: Radiation therapy in the management of breast cancer. Surg Clin North Am. 93:455–471. 2013. View Article : Google Scholar : PubMed/NCBI
28	Seol JY, Park KH, Hwang CI, Park WY, Yoo CG, Kim YW, Han SK, Shim YS and Lee CT: Adenovirus-TRAIL can overcome TRAIL resistance and induce a bystander effect. Cancer Gene Ther. 10:540–548. 2003. View Article : Google Scholar : PubMed/NCBI
29	Hu Y, Ouyang W, Wu F, Cao CH, Wang K, Liao ZK, Zhong YH, Zhou FX, Liu SQ, Xia L, et al: Enhanced radiosensitivity of SW480 cells via TRAIL up-regulation mediated by Egr-1 promoter. Oncol Rep. 22:765–771. 2009.PubMed/NCBI
30	Cheng G, Kong D, Hou X, Liang B, He M, Liang N, Ma S and Liu X: The tumor suppressor, p53, contributes to radiosensitivity of lung cancer cells by regulating autophagy and apoptosis. Cancer Biother Radiopharm. 28:153–159. 2013. View Article : Google Scholar : PubMed/NCBI
31	Pauwels B, Korst AE, de Pooter CM, Pattyn GG, Lambrechts HA, Baay MF, Lardon F and Vermorken JB: Comparison of the sulforhodamine B assay and the clonogenic assay for in vitro chemoradiation studies. Cancer Chemother Pharmacol. 51:221–226. 2003.PubMed/NCBI